Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10587921 | Bioorganic & Medicinal Chemistry Letters | 2013 | 4 Pages |
Abstract
The neonatal Fc receptor, FcRn, prolongs the half-life of IgG in the serum and represents a potential therapeutic target for the treatment of autoimmune disease. Small molecules that block the protein-protein interactions of human IgG-human FcRn may lower pathogenic autoantibodies and provide effective treatment. A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Zhaolin Wang, Cara Fraley, Adam R. Mezo,